Sarafraz K. Niazi, PhD, previews the new year and his hopes for the end of clinical efficacy testing for biosimilar approvals using examples from history of other scientific concepts that took time to gain traction.
One of the best measures of the rise of science is the PubMed profile of peer-reviewed literature. The first mention of “biosimilarity” was made in 1977, but the text is unavailable. Since then, about 6,000 papers, more than half of them over the past 5 years, have discussed biosimilars. The first clinical trial of a biosimilar was reported in 2007 for growth hormone, and since then, 529 trials have been published, 470 being randomized controlled studies. Now, there are around 1500 review articles and systemic reviews. These gurus tell you what a biosimilar is and rarely present science ahead of their perceptions.
There are 852 clinical trials listed in clinicaltrials.gov, with 300 completed, 190 with results, and 118 with study protocols. Ninety-two thousand subjects were enrolled with a per capita cost of $55,000, leading to an approximate cost of over $5 billion. While this is still smaller than new biological drug development, the biosimilars do not get 12 years of exclusivity. Not surprising is the cost distribution, wherein more than two-thirds of the development cost goes to pay for efficacy trials, making this a significant roadblock for smaller companies entering the market.
I have written extensively on the issue of the redundancy of clinical trials and shared the extensive pharma views that continue to demand this testing as a talking point with prescribers without any risk of failure. It is difficult, as history tells us, to break a belief, mainly when the proposal is contrarian, but I also believe that eventually the scientific principles prevail. Here are a few examples to entertain you:
Ignaz Semmelweis, an obstetrician in 1847, showed that hand washing dramatically reduced mortality in childbirth. Despite this, his ideas were dismissed, and he was tragically institutionalized, dying in an asylum in 1865. His hand-washing practices were not adopted until after his death.
Aristarchus of Samos, in Ancient Greece, proposed a heliocentric solar system around 310 BC, suggesting that Earth and other planets orbit the sun. His ideas were ignored, and Nicolaus Copernicus’ theory reconsidering it wouldn’t be published for another 1800 years.
Gregor Mendel, a monk, established the foundation of genetics in the 19th century. His work on heredity was only recognized 16 years after his death and 34 years after his initial publication.
Lastly, Amedeo Avogadro's hypothesis, now known as Avogadro's Law, proposed that equal volumes of gases contain an equal number of molecules as long as they are under the same temperature and pressure conditions. His hypothesis was initially rejected but gained acceptance by 1870, long after his death.
Before I die, I hope we will come to grips with the reality that testing biosimilars for efficacy testing is just as futile as trying to understand quantum physics, at least for me.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
The Role of Biosimilars: Advancing Access, Financial Health, and System Sustainability
March 11th 2024Kashyap Patel, MD, CEO of Carolina Blood and Cancer Care, a member of the Community Oncology Alliance, and member of The Center for Biosimilars® Advisory Board, glances back at the development of the biosimilar industry and the last 5 years of progress.
The Subcutaneous Revolution: Zymfentra and the Future of IBD Care With Dr Andres Yarur
December 17th 2023On this episode of Not So Different, Andres Yarur, MD, a researcher and associate professor of medicine at Cedars-Sinai Medical Center, discusses the significance of the FDA approval for Zymfentra, the world's first subcutaneous infliximab product, for patients with inflammatory bowel disease (IBD).
BioRationality: EMA Announces Readiness to Waive Comparative Efficacy Studies of Biosimilars
March 4th 2024Sarfaraz K. Niazi, PhD, takes a look at the European Medicines Agency's (EMA) announcement that it will investigate whether comparative efficacy tests should be needed for a biosimilar to receive regulatory approval.
Celltrion, Samsung Bioepis Unveil New Biosimilar Data in CD, UC at ECCO 2024
February 23rd 2024At the Congress of European Crohn’s and Colitis Organisation (ECCO), Celltrion and Samsung Bioepis presented new finding from their respective biosimilar analyses, demonstrating positive safety and efficacy measures for the biosimilars as treatments for Crohn disease (CD) and ulcerative colitis (UC).